Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572850 | 0.82 | GSK3B (0.49) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3566809 | 0.79 | GSK3B (0.41) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3629437 | 0.79 | GSK3B (0.42) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3569015 | 0.78 | GSK3B (0.40) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3574900 | 0.78 | GSK3B (0.41) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3564745 | 0.75 | GSK3B (0.54) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3570867 | 0.72 | GSK3B (0.39) | GSK3BCYP2D6 | |
| SCHEMBL3568860 | 0.72 | GSK3B (0.51) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3572370 | 0.72 | GSK3B (0.46) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL13721924 | 0.72 | GSK3B (0.61) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269257-A1 | Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269257-A1 | Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives | CDK5, PSEN2, PSEN1 | GSK3B 6/4885CYP2D6 3940/4885CYP1A2 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.